Key result
Paclitaxel-coated balloons linked to ~26-point lower binary restenosis vs POBA in de novo lesions.
Observational (n=72)
Yes
Answers are grounded in this paper and cite their sources.
PURPOSE: This study compared the angiographic outcomes of paclitaxel-coated balloon (PCB) versus plain old balloon angioplasty (POBA) treatment for de novo coronary artery lesions. At present, there is no available data comparing the efficacy of PCB versus POBA for the treatment of de novo coronary lesions. MATERIALS AND METHODS: This multicenter retrospective observational study enrolled patients with de novo coronary lesions with a reference vessel diameter between 2.5 mm and 3.0 mm and lesion length ≤ 24 mm who were successfully treated with PCB or POBA. Angiographic measurements and quantitative coronary analysis were performed before and after the procedure, and at 9 months follow-up. RESULTS: A total of 72 patients (49 receiving PCB and 23 receiving POBA) were enrolled in this study. Late luminal loss was -0.12 ± 0.30 mm in the PCB group and 0.25 ± 0.50 mm in the POBA group (p<0.001). There was a higher percentage of binary restenosis (diameter stenosis ≥ 50%) in POBA, compared to PCB (30.4%, n=7 vs. 4.1%, n=2, p<0.001). Target vessel revascularization was higher in the POBA group (13.0%, n=3 vs. 0%, p=0.033). CONCLUSION: PCB treatment of de novo coronary lesions showed better 9-month angiographic outcomes than POBA treatment alone.
No takes yet. Share an insight, caveat, or question.
Her et al. (2016) conducted an observational in de novo coronary artery lesions (n=72). Paclitaxel-coated balloon (PCB) vs. Plain old balloon angioplasty (POBA) was evaluated on Binary restenosis (diameter stenosis ≥ 50%) (p=<0.001). Paclitaxel-coated balloon treatment for de novo coronary lesions yielded lower binary restenosis (4.1% vs 30.4%, p<0.001) and late luminal loss (-0.12 vs 0.25 mm) compared to POBA at 9 months.
Synapse has enriched 10 related papers. Consider them for comparative context: